Table 3. . Associations between the low & elevated STK1p values & clinical pathological characteristics after two-cycle chemotherapy (Chi-square test).

Group	STK1p ≤0.6 pM (n = 58)	STK1p >0.6 pM (n = 43)	p-value
Clinical stage, n = 95
Early/middle (I–IIIA), n = 24	19	5
Advanced (IIIB + IV), n = 71	36	35	0.015
Histological type, n = 98
AC, n = 70	40	30
SCC, n = 28	17	9	0.149
Age, n = 101
≤60 years, n = 34	20	14
>60 years, n = 67	36	31	0.626
Gender n = 101
M, n = 68	40	38
F, n = 33	17	6	0.054
RECIST, n = 101
OR (CR + PR), n = 32	18	14
NR (PD + SD), n = 69	31	38	0.049
Clinical stage: IA–IV, n = 101
Surgery + chemo., n = 47	31	16	0.010
Chemo-alone, n = 54	23	31
Clinical stage: IIIB + IV, n = 73
Surgery + chemo., n = 23	14	9
Chemo.-alone, n = 50	27	23	0.529
Surgery + chemo., n = 42
Stage I–IIIA, n = 24	18	6
Stage IIIB + IV, n = 18	8	10	0.044

Note: Bold values were used to indicate for the readers that these values are statistically significant.

AC: Adenocarcinoma; Chemo.: Chemotherapy; CR: Complete response; NR: No response; OR: Objective response; PD: Progressive disease; PR: Partial response; RECIST: Response Evaluation Criteria in Solid Tumors; SCC: Squamous cell carcinoma; SD: Stable disease; STK1p: Serum thymidine kinase 1 concentration.